Effectiveness of rhIGF-I treatment in a girl with Leprechaunism

Clemens Kamrath, Claudia Boettcher and Stefan A. Wudy

Justus-Liebig-University, Centre of Child and Adolescent Medicine, Division of Pediatric Endocrinology and Diabetology, Giessen, Germany

Background
Infants with severe insulin resistance syndrome show failure to thrive.

Objective and hypotheses
Effect of rhIGF-I treatment on growth in a patient with severe insulin resistance syndrome.

Methods
Case report.

Results
The patient is a now 4 ½-yr old Caucasian girl of unrelated healthy parents. She was born after a 40 week gestation as a small for gestational age infant with a birth weight of 1970 g (-3.56 SDS). After birth she developed high blood glucose levels of >400 mg/dL with high levels of insulin (>2,000 mU/mL) and C-peptide (>60 ng/mL), fastening hypoglycaemias and high blood pressure. At the age of 22 months she was admitted to our hospital. She had decreased subcutaneous fat, hypertrichosis, ovoidal cysts, and acanthosis nigricans. She was extremely short and had very low levels of IGF-I and IGFBP-3 (Table 1). We started treatment with rhIGF-I (Increlex®, Ipsen, Ettingen, Germany) with a dose of twice daily 0.6 mg s.c. at the age of 35 months. She showed a catch-up growth of +1.0 SDS over the first 19 months (Fig. 1). Levels of IGF-I were in the middle-normal range befor and in the upper normal range two hours after s.c. injection (Table 1). Levels of IGFBP3 remained low (Table 1). Treatment was well tolerated, blood glucose levels remained stable and haemoglobin A1c level was within the normal range (5.7%).

Table I

<table>
<thead>
<tr>
<th>Age (months)</th>
<th>Height (cm) (SDS)</th>
<th>Weight (kg) (SDS)</th>
<th>Increlex® dosage (µg/kg/d)</th>
<th>IGF-I (µg/L) (SDS)</th>
<th>IGFBP-3 (mg/L) (SDS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>73.4 (-4.1)</td>
<td>8.0 (-3.9)</td>
<td>-</td>
<td>1 (-8.0)</td>
<td>0.16 (-9.4)</td>
</tr>
<tr>
<td>35</td>
<td>80.4 (-4.2)</td>
<td>8.8 (-4.9)</td>
<td>-</td>
<td>2 (-7.9)</td>
<td>0.55 (-5.6)</td>
</tr>
<tr>
<td>44</td>
<td>87.3 (-3.5)</td>
<td>10.6 (-3.9)</td>
<td>113 (2 x 0.6 mg)</td>
<td>91 (-0.1)</td>
<td>0.82 (-4.3)</td>
</tr>
<tr>
<td>54</td>
<td>94.1 (-3.2)</td>
<td>11.9 (-3.7)</td>
<td>117 (2 x 0.7 mg)</td>
<td>225 (+1.7)</td>
<td>N.D.</td>
</tr>
</tbody>
</table>

Start Increlex®: 2 x 0.6 mg/d (136 µg/kg/d) at the age of 35 months

Figure 1

Conclusions
This leprechaun patient has an IGF-I deficient state and rhIGF-I treatment induced catch-up growth.